LifeMD 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Third-quarter revenue was $44.6 million, down approximately 7% from $47.7 million in the prior-year period and below the guidance range of $48 to $51 million.
- Adjusted EBITDA was a loss of $0.4 million, within guidance and improved from a $3.5 million loss in the second quarter; GAAP net loss from continuing operations attributable to common stockholders was $5.2 million, or 11 cents per share.
- Gross profit was $36.4 million, compared with $40.7 million a year ago, and gross margin was approximately 82%, versus approximately 89% in the second quarter and 85% a year ago.
- Selling and marketing expense was $18.5 million, down $9.5 million, or 34%, from the second quarter and down 18% year over year; general and administrative expense was $14.7 million, up 6% year over year.
- LifeMD ended the quarter with approximately 350,000 active subscribers, up 13% year over year and nearly flat from the second quarter, and approximately 104,000 weight management patients.
- Pharmacy orders grew 17% from the second quarter to the third quarter, September volume was up 58% year over year, and October orders rose 27% from September; orders for personalized non-GLP-1 compounded therapies tripled from the second quarter to the third.
- LifeMD ended the quarter with $21.9 million in cash and no debt, and subsequently closed a $12.5 million non-convertible senior secured term loan with Avenue Capital, replacing its revolving credit facility with Citizens Bank.
- Management said immaterial errors in recording net revenues for certain third-party pharmacy arrangements primarily affected 2024 and 2025, were immaterial to previously issued financial statements, and had no effect on cash in any period presented.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon, and thank you for joining us today to discuss LifeMD's results for the third quarter ending September 30, 2026. Joining the call today are Justin Schreiber, Chairman and Chief Executive Officer, and Atul Kavthekar, Chief Financial Officer. Following management's prepared remarks, we will open the call for a question-and-answer session. Before we begin, I would like to remind everyone that during this call, the company will make a number of forward-looking statements, which are subject to numerous risks and uncertainties that may cause actual results to differ materially from those projected. These risks and uncertainties are described in the company's 10-K and 10-Q filings and in other filings LifeMD may make with the SEC from time to time. Forward-looking statements made during this call are based on information available to the company as of today, November 12, 2026.
The company assumes no obligation to update or revise any forward-looking statements after today's call, except as required by law. Management will also discuss certain non-GAAP financial measures that the company believes are useful in evaluating its performance. Reconciliation to the most comparable GAAP measures can be found in the press release issued earlier today. Today's call is being recorded and will be available for replay in the investor relations section of the company's website. Now, I'd like to turn the call over to LifeMD's Chairman and Chief Executive Officer, Justin Schreiber.
Justin? Thank you, operator, and good afternoon, everyone.
Earlier this afternoon, we issued our third quarter release and filed our 10-Q. Let me start with the numbers. Revenue was $44.6 million, below the range we guided to. Adjusted EBITDA was slightly negative, within our guidance range, and a $3.1 million improvement over the second quarter. We are also resetting our outlook for the fourth quarter and the full year. Last quarter, I told you we expected to exit the year at a $250 million revenue run rate. We won't. We now expect to exit at roughly a $200 million revenue run rate. There were three things that drove the shortfall. First, our guidance assumed our branded GLP-1 fulfillment program would begin earlier in the quarter. Finalizing and implementing those arrangements took longer than we planned, so less of that revenue landed in the third quarter.
This was a timing issue, not a demand issue. Arrangements with manufacturers are now in place, and the program is ramping, as I'll discuss in a moment. Second, we took a conservative approach to new patient acquisition. We cut marketing spend by almost a third quarter-over-quarter, while we improved our technology platform and patient experience to drive better unit economics and patient retention. We also chose longer patient subscription commitments over upfront revenue. Those choices cost us revenue this quarter. Third, and this is related to the second, some of the patient cohorts we brought on earlier this year didn't perform the way we expected. This is a big part of why we pulled back. We made pricing and plan changes to address that, and rather than scale spend before we knew those changes were working, we chose to hold back until our new cohorts proved out.
The early results are encouraging, and I'll come back to those shortly. The most important takeaway for our shareholders is that despite some continued softness in the business, we are in a strong liquidity position, and I believe have an amazing year of high-quality growth ahead of us. I'm going to keep the rest of my remarks short, because the message is simple. It comes down to five things. First, we are more confident than ever in our decision to build LifeMD's Weight Management offering around branded GLP-1s. In the last 30 days, we completed arrangements with both Eli Lilly and Novo Nordisk that enable us to integrate self-pay GLP-1 medications directly into our pharmacy operations, further expanding access to these products by removing friction from the patient experience. Second, our enterprise business is off to a strong start.
Our AT&T collaboration is live, with 100 million customers and 110,000 employees now eligible for access to high-quality care and prescription medications through LifeMD. Third, the unit economics of our core programs continue to improve, driving us towards our goal of sustained profitability, coupled with strong top-line performance. Fourth, we are executing a plan to reduce operating expenses by 30% from the first quarter of 2026 to the first quarter of 2027. We have made meaningful progress and will reach the halfway point this quarter. Fifth, early next year, we expect to begin rolling out what we believe will be the most significant evolution of the LifeMD patient experience since our launch. Let me take them in order.
In the past 30 days, we entered arrangements with Novo Nordisk and Eli Lilly, enabling LifeMD's pharmacy to fulfill and ship nearly every branded GLP-1 on the market, Wegovy pill, Ozempic, Zepbound, and Mounjaro, directly to our patients' doors. This is a critical milestone in our overall strategic vision. Think about what this means for a patient. Too often, getting on a branded GLP-1 means a prescription from one place and a trip to a pharmacy counter or another e-commerce platform, with no connection in between. At LifeMD, it can all happen within one connected ecosystem. The provider who prescribes, the pharmacy that fills and ships to the patient's door, and the care and support teams that stay with them through every refill and dose change are all able to utilize the same platform. There's no need for a third-party handoff and no gap in care.
It is simpler for the patient, it gets them started sooner, and it keeps them on the treatment their provider intended. This creates better outcomes for patients, which is the main driver of every decision we make at LifeMD. Now think about what it means for our economics. Patients eligible for self-pay branded GLP-1 medications, whose scripts had been filled exclusively through third-party pharmacies, are now able to fill those scripts with LifeMD Pharmacy. Because we now report that revenue on a gross basis, our gross margin percentage will come down, but the revenue and gross profit dollars we earn from each patient on a GLP-1 therapy will go up. Atul will walk you through it. Our pharmacy is what makes this possible, and it is gaining momentum. Pharmacy orders grew 17% from the second quarter to the third, and September volume was up 58% year over year.
We began fulfilling Novo Nordisk medicines in September, and October orders rose another 27% from there. The pharmacy's role also reaches well beyond GLP-1s. It now produces personalized non-GLP-1 compounded therapies that support our men's and Women's Health programs, and orders for those therapies tripled from the second quarter to the third. This quarter, we are launching an updated storefront, giving patients a simple way to browse and order these therapies directly, and we expect it to accelerate that growth meaningfully. We built our pharmacy to own the patient experience. It has become one of our most important strategic advantages, and it will be a key part of our model going forward. Two years ago, we made a decision that some investors did not like. We walked away from mass-market GLP-1 compounding and doubled down on FDA-approved medications. It cost us growth and profit in the short term.
However, this quarter is proof that the decision was right, and the timing could not be better. Here is why. A new generation of branded obesity medicines is approaching the market. Novo Nordisk CagriSema combines semaglutide with an amylin analog, cagrilintide, in a single once-weekly injection. In its pivotal trial, patients lost 22.7% of their body weight at 68 weeks, versus 16.1% on semaglutide alone. Novo filed with the FDA last December, and a decision is expected in the coming months. This is especially exciting for patients on or considering our Women's Health program for menopausal care. In Novo's recently announced post-hoc analysis of REDEFINE 1, women with obesity or who are overweight lost an average of 24.8% of their body weight during perimenopause, and 23.1% after menopause, with reductions in waist circumference observed across menopausal stages.
This highlights a unique synergy created by the breadth of our specialty care platform. Unlike other providers, LifeMD can bring women's health, Weight Management, labs, pharmacy, and ongoing clinical care together in one connected experience, further reinforcing the value of the healthcare ecosystem we continue to build. That overlap between metabolic care and women's health is one example of why the next generation of GLP-1 therapies is so important to LifeMD, and CagriSema is only one of the major advances now approaching the market. We believe next-generation GLP-1 therapies will drive continued growth in obesity treatment, a market projected to reach $130 billion a year by 2030, and one of the largest in the history of American healthcare. Here is the strategic point I want investors to focus on. These therapies do not just raise the standard for weight loss.
They could fundamentally reshape the competitive structure of this market. The compounded GLP-1 market expanded under temporary shortage conditions that allowed hundreds of direct marketing companies to sell copies of semaglutide and tirzepatide. Those shortages have ended, and we do not believe the same pathway will exist for this next generation of medicines. The FDA has stated that certain next-generation molecules cannot currently be used in compounding under federal law, and CagriSema is a proprietary, fixed-dose, dual-peptide combination. As a result, we do not expect compounded versions of next-generation medicines to be available at scale. That distinction matters because much of today's virtual weight loss market was built around compounded GLP-1 access. As treatment shifts toward next-generation branded medicines, we expect the competitive field to narrow. The companies positioned to lead will be those with brand equity, serious clinical infrastructure, national pharmacy capabilities, and meaningful strategic partnerships.
That is where LifeMD stands apart. We ended the quarter with approximately 104,000 Weight Management patients, and we already have the clinical infrastructure and pharmacy capabilities required to bring these medicines to patients at scale. As the category moves toward next-generation branded therapies, we believe LifeMD will be one of the best-positioned virtual care and pharmacy platforms in the country. Second, enterprise. On September 15, we announced our collaboration with AT&T, which became the first and only carrier to offer its customers free access to a virtual healthcare platform. AT&T's 100 million wireless and fiber customers and its 110,000 U.S. employees are eligible for a complimentary LifeMD membership, a $228 annual value. We launched in 11 states, reaching roughly 29 million customers, and we expect to go national this January. On November 2, AT&T sent its first dedicated LifeMD email to approximately 6 million customers.
It is the first of many planned outreaches to the AT&T base that we expect to build in waves as we expand nationally in January. It is early, and we will report results as the program scales. Why does this matter? AT&T gives us access to patients at a small fraction of the acquisition cost we typically see through paid media, places LifeMD in front of tens of millions of American households, and validates our platform with one of the largest and most trusted companies in the country. It demonstrates that LifeMD can serve not only as a direct-to-consumer healthcare brand, but also as the healthcare infrastructure behind major consumer and employee platforms. We view AT&T as a blueprint for a broader enterprise distribution model. We are not replacing our direct-to-consumer business. We are adding a lower-cost and more defensible growth channel alongside it.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
7 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
